During the corresponding time, Sol Gel Technologies Ltd recorded a revenue increase by 68.04 % year on year, While revenue at the Sol Gel Technologies Ltd 's corporate clients
Sol Gel Technologies Ltd's Comment on Sales, Marketing and Customers
The company operates in pharmaceutical markets with products including Twyneo, Epsolay, and product candidates such as SGT-610. Its patent portfolio spans multiple countries, including the United States, Europe, United Arab Emirates, ARIPO, Australia, Brazil, Canada, Chile, China, Eurasia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Singapore, Thailand, Ukraine, and South Africa. The company holds trademarks for SGT-610 under the name "Saquelta" registered in various countries worldwide. Named customers and market participants include PellePharm and Royalty Security LLC.
TWYNEO, developed by Sol-Gel, is a novel fixed-dose combination therapy for acne vulgaris. It combines minocycline, one of the most widely prescribed oral antibiotics for acne, with Sol-Gel s proprietary 5% benzoyl peroxide (BPO) gel. This groundbreaking dual-action formulation effectively targets both the underlying causes of acne and reduces the presence of P. acnes bacteria on the skin s surface.Acne affects millions of people worldwide and can have a significant impact on their quality of life. While there are various available treatments, the efficacy and tolerability of many options remain areas of concern. The introduction of TWYNEO offers new hope for patients, providing a convenient once-daily appli...
Sol-Gel Technologies Begins Phase 3 Study for SGT-610, a Potential Groundbreaking Treatment for Gorlin Syndrome NESS ZIONA, Israel, Nov. 30, 2023 - Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a renowned dermatology company specializing in innovative therapies for severe skin conditions, has recently commenced Phase 3 testing for SGT-610, a promising new topical hedgehog inhibitor. The study aims to evaluate the gel s effectiveness in preventing the development of basal cell carcinoma (BCC) lesions in patients suffering from Gorlin syndrome, a hereditary condition characterized by a high risk of skin cancer. SGT-610, otherwise known as patidegib gel, 2%, has shown significant potential in combating Gor...
Sol Gel Technologies Ltd’s Comment on Sales, Marketing and Customers
The company operates in pharmaceutical markets with products including Twyneo, Epsolay, and product candidates such as SGT-610. Its patent portfolio spans multiple countries, including the United States, Europe, United Arab Emirates, ARIPO, Australia, Brazil, Canada, Chile, China, Eurasia, Israel, Japan, South Korea, Mexico, Malaysia, New Zealand, Singapore, Thailand, Ukraine, and South Africa. The company holds trademarks for SGT-610 under the name "Saquelta" registered in various countries worldwide. Named customers and market participants include PellePharm and Royalty Security LLC.
Sources:
Sol gel Technologies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sol gel Technologies Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Sol gel Technologies Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.65 %